On Mar. 9, 2021, NanoViricides announced that NV-CoV-2 and NV-CoV-2-R were found to be highly effective against a fully lethal direct-lung coronavirus infection in rats based on multiple indicators. The Company was preparing a pre-IND application encompassing its two clinical drug candidates for the treatment of COVID-19 infected patients.